Curis Stock Forecast
NASDAQ: CRISHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 0.66 -6.96%
CRIS analyst consensus
Consensus (4 analysts)
none
Avg. price target
$42.67+5914.94%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Curis (2026-10-09), 4 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $42.67, with a high estimate of $65.00 and a low estimate of $20.00. The average target implies upside of 5914.9% from the current price of $0.7094.
The spread between the highest and lowest targets is 225.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CRIS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 25% |
| Buy | 3 | 75% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $20.00 | +2719.28% |
| Average target | $42.67 | +5914.94% |
| High target | $65.00 | +9062.67% |
How analysts view Curis's peers
| Company | Consensus | Price | Avg. target | Implied move |
|---|---|---|---|---|
| SLXN | none | 0.2349 | $5.00 | +2028.57% |